Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AJANTPHARM | NSE
9.90
0.36%
Healthcare
Drug Manufacturers-Specialty & Generic
31/03/2024
21/04/2026
2,791.20
2,784.00
2,816.00
2,776.00
Ajanta Pharma Limited a specialty pharmaceutical formulation company together with its subsidiaries develops manufactures and markets finished dosages. The company markets and serves various therapeutic segments such as anti-biotic anti-malarial diabetic cardiology gynecology respiratory and general health products dermatology and pain management areas. It also provides tablets capsules powder liquid jelly ointments eye drops active pharma ingredient. The company serves in India Africa rest of Asia the United States and internationally. The company was founded in 1973 and is headquartered in Mumbai India.
View LessStrength based on increasing price with high volume
Low 6-Month Volatility (<30%)
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Operating Margin (> 25%)
Strong Revenue Growth (> 10%)
Price Below SMA10D
Midcap (2B - 10B USD)
Rich in Valuation (Price to Book > 8)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
25.8%1 month
28.2%3 months
26.2%6 months
25.3%47.17
-
11.33
0.01
0.01
30.61
9.36
-
12.23B
353.54B
3.78B
1.13
25.89
18.10
12.10
23.47
-
-
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
237.40
Range1M
261.20
Range3M
568.00
Rel. volume
1.49
Price X volume
386.86M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Ipca Laboratories Limited | IPCALAB | Drug Manufacturers-Specialty & Generic | 1476.5 | 374.59B | 0.54% | 72.46 | 22.72% |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | Drug Manufacturers-Specialty & Generic | 1992.9 | 309.53B | 0.09% | 51.20 | 12.92% |
| Wockhardt Limited | WOCKPHARMA | Drug Manufacturers-Specialty & Generic | 1407.7 | 215.97B | 0.30% | n/a | 70.14% |
| AstraZeneca Pharma India Limited | ASTRAZEN | Drug Manufacturers-Specialty & Generic | 8452 | 211.30B | -0.93% | 197.18 | 0.65% |
| Neuland Laboratories Limited | NEULANDLAB | Drug Manufacturers-Specialty & Generic | 14920 | 209.50B | -1.86% | 53.76 | 7.44% |
| Dr. Reddy's Laboratories Limited | DRREDDY | Drug Manufacturers-Specialty & Generic | 1220.6 | 203.34B | -0.97% | 20.23 | 10.41% |
| Piramal Pharma Limited | PPLPHARMA | Biotechnology | 150.81 | 199.37B | 1.36% | 805.68 | 59.54% |
| NATCO Pharma Limited | NATCOPHARM | Drug Manufacturers-Specialty & Generic | 1055.65 | 189.08B | -4.04% | 15.31 | 6.34% |
| Eris Lifesciences Limited | ERIS | Drug Manufacturers-Specialty & Generic | 1376 | 187.55B | -3.94% | 48.08 | 107.55% |
| Syngene International Limited | SYNGENE | Biotechnology | 444.65 | 178.39B | 1.88% | 71.45 | 13.66% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| AFFLE | AFFLE | Advertising Agencies | 1462.9 | 204.59B | 1.25% | 67.64 | 7.31% |
| Vedant Fashions Limited | MANYAVAR | Apparel Retail | 450.85 | 110.28B | 0.48% | 84.26 | 27.74% |
| Vertoz Advertising Limited | VERTOZ | Advertising Agencies | 50.53 | 44.32B | -5.04% | 48.67 | 10.74% |
| Signpost India Limited | SIGNPOST | Advertising Agencies | 271.87 | 15.94B | 0.54% | 30.54 | 80.30% |
| "SAI SILKS (KALAMANDIR) LIMITED " | KALAMANDIR | Apparel Retail | 100.64 | 14.83B | -0.92% | 28.83 | 43.67% |
| V2 Retail Limited | V2RETAIL | Apparel Retail | 197.59 | 7.05B | 3.12% | 120.49 | 191.28% |
| Bhagyanagar India Ltd | BHAGYANGR | Copper | 214.72 | 6.94B | -0.03% | 36.36 | 52.08% |
| Madhav Copper Limited | MCL | Copper | 61 | 1.68B | -1.98% | 82.22 | 32.14% |
| Cubex Tubings Limited | CUBEXTUB | Copper | 93.13 | 1.35B | 1.38% | 35.85 | 21.78% |
| Touchwood Entertainment Limited | TOUCHWOOD | Advertising Agencies | 74.4 | 829.47M | -0.24% | 50.06 | 4.88% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 30.61 | 24.85 | Expensive |
| Ent. to Revenue | 9.36 | 11.40 | Par |
| PE Ratio | 47.17 | 51.36 | Par |
| Price to Book | 11.33 | 6.83 | Expensive |
| Dividend Yield | 1.13 | 0.52 | Leader |
| Std. Deviation (3M) | 26.18 | 42.17 | Lower Risk |
| Debt to Equity | 0.01 | 0.35 | Cheaper |
| Debt to Assets | 0.01 | 0.17 | Cheaper |
| Market Cap | 353.54B | 290.82B | Market Leader |